Who We Are
We are a biopharmaceutical company pioneering delivery of RNA therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. Our proprietary technology leverages the targeted RNA delivery platform initially designed at Avidity, which combines the tissue selectivity of mAbs and other targeted delivery ligands with the precision of oligonucleotides.
This unique combination is designed to allow selective targeting of the underlying genetic drivers of disease that were previously undruggable. Through targeted, non-viral delivery of siRNA to cardiac tissues, our approach has the potential to overcome key limitations of nonspecific viral and nanoparticle-based delivery systems, including challenges related to tissue specificity, immunogenicity, and redosing.
Who we are
Meet the Team
Kath Gallagher
Chief Executive Officer
Kathleen Gallagher is the Chief Executive Officer of Atrium Therapeutics and is also a member of the Company’s Board of Directors, with exceptional executive management expertise and tenured experience in the biopharmaceutical industry. She has more than 20 years of experience and has led investor relations, portfolio strategy, program management and corporate affairs for preclinical to commercial stage companies, including Avidity Biosciences, Akcea Therapeutics and Merrimack Pharmaceuticals. Notably, at Akcea (acquired by Ionis Pharmaceuticals) her communications strategy and relationship building expertise were essential through the development and commercial launches of rare disease therapies Tegsedi® and Waylivra®. She also held roles of increasing responsibility during her 13-year tenure at Merrimack, where she provided leadership and direction through multiple financing rounds including an IPO and through the launch of the pancreatic cancer therapy ONIVYDE®. Ms. Gallagher earned her B.S. degree in English from Boston University.
Steve Hughes, MD
Chief Medical Officer
Dr. Steve Hughes is the Chief Medical Officer of Atrium Therapeutics, with more than 25 years of experience in the biopharmaceutical industry. He has contributed to more than 50 clinical trials and multiple product filings and launches across cardiovascular, neurology and rare disease therapeutic areas at Avidity Biosciences, Ionis Pharmaceuticals, Biogen, CSL Behring and Sanofi. His previous positions include the Chief Medical Officer at Avidity, Arcturus and Organovo, Chief Clinical Development Officer at Ionis Pharmaceuticals and clinical leadership positions at Biogen, CSL Behring and Sanofi. Dr. Hughes is board certified in pharmaceutical medicine and received his medical degree from Imperial College, London. He also has an MBA from Imperial College Business School.
Rocio Martin Hoyos
Chief Strategy Officer
Rocio Martin Hoyos is Chief Strategy Officer at Atrium Therapeutics, a seasoned strategist with more than 20 years of experience in management and commercial roles in the biopharmaceutical industry. She has held leadership positions at Avidity Biosciences, Kronos Bio, Audentes Therapeutics, Ultragenyx and Celgene across multiple therapeutic areas. Notably, she served as SVP and Global Program Head for FSHD at Avidity, SVP of Corporate Strategy at Kronos Bio, a precision oncology company, and gained early expertise in rare disease at Audentes (Astellas Gene Therapies) and Ultragenyx. Additionally, Rocio has led marketing, product planning, and launch readiness in global markets. She holds an MSc in biochemistry from Universidad Autónoma de Madrid and an MBA from IESE Business School.
Stephanie Kenney
Chief Corporate Affairs Officer
Stephanie Kenney is Chief Corporate Affairs Officer at Atrium Therapeutics. She has more than 25 years of experience in the biopharmaceutical industry leading corporate affairs, investor relations, and marketing at preclinical to commercial stage companies in autoimmune, cardiovascular, and renal therapeutic areas. She has held roles of increasing responsibility at Avidity Biosciences, AstraZeneca and Hansa Biopharma. Ms. Kenney earned her B.S. degree in communications from Mansfield University.
Brendan Winslow
Chief Financial Officer
Brendan Winslow is Chief Financial Officer at Atrium Therapeutics, with extensive experience in financial leadership roles in the biotechnology and healthcare industries. He has held senior positions involving global operations, commercialization, and strategic transformations at Avidity Biosciences, Acadia Pharmaceuticals and Baxter International. Mr. Winslow holds an MBA from the Kellogg School of Management at Northwestern University and a B.S. degree in finance from Miami University, and is a Certified Management Accountant.
Husam S. Younis, PhD, PharmD
Chief Scientific Officer
Dr. Husam Younis is Chief Scientific Officer at Atrium Therapeutics, with more than 20 years of experience in drug discovery and development, including in rare disease. He has held senior leadership roles in research and development science at Avidity Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals and Pfizer. His experience spans multiple drug modalities and therapeutic areas and he has led research and development teams to advance multiple programs from preclinical research to first-in-human studies and to BLA submission. Dr. Younis completed his graduate training in pharmacology and toxicology and pharmacy practice at the College of Pharmacy at the University of Arizona.
Board of Directors
Sarah Boyce
Chair of Board
Sarah Boyce has been Chair of the Company’s Board of Directors since December 2025. Previously, she served as President and Chief Executive Officer and a member of the Board of Directors at Avidity Biosciences since October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity was marked by transformative leadership, starting with the company’s successful Series C funding round and IPO. She continued to drive the company’s evolution from a research and development entity to a biopharmaceutical company through the advancement of three rare neuromuscular disease therapies into clinical development and the expansion of the broad utility of the company’s RNA technology. Her tenure at Avidity culminated with the approximately $12 billion acquisition by Novartis for its neuroscience pipeline and differentiated RNA-delivery platform. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah currently serves as a member of the board of directors at Contineum Therapeutics, Inc., and Abcuro, Inc.
Carsten Boess
Board Member
Carsten Boess has been a member of the Company’s Board of Directors since February 2026. He has nearly 30 years of industry experience as a finance executive and board member, and brings a wealth of experience in financing, and leading and growing biotechnology companies. Mr. Boess also serves on the Board of Directors and is Chair of the Audit Committee at Rocket Pharmaceuticals, a public biopharmaceutical company, and was previously a board member at Avidity. Prior to serving in his board roles, Mr. Boess held executive level positions within the biopharmaceutical industry including Executive Vice President of Corporate Affairs at Kiniksa Pharmaceuticals, Senior Vice President and Chief Financial Officer at Synageva Biopharma Corporation (until its acquisition by Alexion Pharmaceuticals) and Chief Financial Officer at Alexion. In addition, Mr. Boess served as Chief Financial Officer, and later, as Vice President of International Operations at Insulet Corporation, Executive Vice President of Finance at Serono Inc., and in several financial executive roles at Novozymes of North America and Novo Nordisk in France, Switzerland and China. During his tenure at Novo Nordisk, he served on Novo Nordisk’s Global Finance Board. Mr. Boess earned his B.S. and M.S. degrees in economics and finance from the University of Odense, Denmark.
W. Michael Flanagan, PhD
Board Member
W. Michael Flanagan has been a member of the Company’s Board of Directors since February 2026. He previously served as Chief Scientific Officer at Avidity. Dr. Flanagan has extensive experience developing multiple therapeutic modalities, including RNA therapeutics, antibody drug conjugates, and bispecific antibodies and small molecules. Prior to joining Avidity, Dr. Flanagan served as Senior Director and Project Team Leader, Oncology and Immunology for Genentech, Inc., where he advanced programs through late-stage research to end of Phase 2 development. Prior to Genentech, he served in roles of increasing responsibility in the biology groups at Sunesis Pharmaceuticals, Inc., Gilead Sciences, Inc., and Merck & Co., Inc. where he was Senior Director of RNA Sciences. Dr. Flanagan holds a B.S. in genetics from the University of California at Davis and a Ph.D. in biological sciences from the University of California at Irvine, and was an American Cancer Society postdoctoral fellow at the Howard Hughes Medical Institute, Stanford University School of Medicine. He has authored more than 50 peer-reviewed publications and holds multiple patents.
Kath Gallagher
Chief Executive Officer
Kathleen Gallagher is the Chief Executive Officer of Atrium Therapeutics and is also a member of the Company’s Board of Directors, with exceptional executive management expertise and tenured experience in the biopharmaceutical industry. She has more than 20 years of experience and has led investor relations, portfolio strategy, program management and corporate affairs for preclinical to commercial stage companies, including Avidity Biosciences, Akcea Therapeutics and Merrimack Pharmaceuticals. Notably, at Akcea (acquired by Ionis Pharmaceuticals) her communications strategy and relationship building expertise were essential through the development and commercial launches of rare disease therapies Tegsedi® and Waylivra®. She also held roles of increasing responsibility during her 13-year tenure at Merrimack, where she provided leadership and direction through multiple financing rounds including an IPO and through the launch of the pancreatic cancer therapy ONIVYDE®. Ms. Gallagher earned her B.S. degree in English from Boston University.
Simona Skerjenac
Board Member
Simona Skerjanec has been a member of the Company’s Board of Directors since February 2026. She has nearly three decades of broad international experience in the pharmaceutical industry and has led multiple research and development efforts that have resulted in regulatory approvals and launches of commercial therapies in therapeutic areas including neurology and cardiology in the U.S. and other countries. Ms. Skerjanec was the Senior Vice President and Global Neuroscience Head at Roche in Switzerland and led the business and global strategy for Roche’s portfolio of neurological and rare diseases, including Ocrevus® for the treatment of multiple sclerosis and a novel monoclonal antibody for the treatment of Alzheimer’s disease. During her nine-year tenure at Roche, she also served as a General Manager of Roche in Portugal. Prior to joining Roche, Ms. Skerjanec was Senior Vice President and Cardiovascular franchise head at The Medicines Company where she held various roles of increasing responsibilities in development and commercialization. She also held positions at Eli Lilly, Pfizer and Johnson & Johnson. Ms. Skerjanec also serves on a board of publicly listed biotechnology firm Immunic Therapeutics and a private technology company, PerceivAI. Ms. Skerjanec holds an M.S. degree in pharmacy from the University of Ljubljana and an MBA from Fairleigh Dickinson University.
Troy Wilson, PhD, JD
Board Member
Dr. Wilson has served as a member of our Board of Directors since February 2026. He is an accomplished biotech leader with a proven track record of founding, building and leading innovative companies that deliver transformative therapies and substantial value to patients and shareholders. Dr. Wilson is a co-founder of Kura Oncology (NASDAQ: KURA), where he has served as President, Chief Executive Officer, and Chairman of the Board since the company’s inception in 2014. He also co-founded Avidity Biosciences and served as Chairman of its Board from inception until its acquisition by Novartis AG. Previously, Dr. Wilson co-founded and served as CEO and President of Araxes Pharma and Wellspring Biosciences, where his teams pioneered discovery and development of small-molecule inhibitors targeting the KRAS oncoprotein — one of oncology’s most challenging targets. Earlier in his career, Dr. Wilson co-founded and served as President and CEO of Intellikine from inception through to acquisition by Takeda Pharmaceutical Company Limited in 2011. He also co-founded Ambrx, where he served as Chief Business Officer, prior to its acquisition by Johnson & Johnson Innovative Medicines in 2024. In addition to his leadership roles, Dr. Wilson currently serves on the boards of Puma Biotechnology, Cartography Biosciences, Montara Therapeutics and Cipher Genetics. He holds a J.D. from New York University and earned his Ph.D. in bioorganic chemistry and B.A. in biophysics from the University of California, Berkeley.